| Year |
Citation |
Score |
| 2014 |
Swensen AM, Niforatos W, Lee CH, Jarvis MF, McGaraughty S. Characterization of the triazine, T4, a representative from a novel series of CaV2 inhibitors with strong state-dependence, poor use-dependence, and distinctively fast kinetics. European Journal of Pharmacology. 745: 234-42. PMID 25446431 DOI: 10.1016/j.ejphar.2014.10.037 |
0.582 |
|
| 2014 |
Zhu CZ, Vortherms TA, Zhang M, Xu J, Swensen AM, Niforatos W, Neelands T, Milicic I, Lewis LG, Zhong C, Gauvin D, Mikusa J, Zhan C, Pai M, Roderwald V, et al. Mechanistic insights into the analgesic efficacy of A-1264087, a novel neuronal Ca(2+) channel blocker that reduces nociception in rat preclinical pain models. The Journal of Pain : Official Journal of the American Pain Society. 15: 387.e1-14. PMID 24374196 DOI: 10.1016/J.Jpain.2013.12.002 |
0.622 |
|
| 2014 |
Xu J, Chu KL, Zhu CZ, Niforatos W, Swensen A, Searle X, Lee L, Jarvis MF, McGaraughty S. A mixed Ca2+ channel blocker, A-1264087, utilizes peripheral and spinal mechanisms to inhibit spinal nociceptive transmission in a rat model of neuropathic pain. Journal of Neurophysiology. 111: 394-404. PMID 24155005 DOI: 10.1152/Jn.00463.2013 |
0.613 |
|
| 2012 |
Swensen AM, Niforatos W, Vortherms TA, Perner RJ, Li T, Schrimpf MR, Scott VE, Lee L, Jarvis MF, McGaraughty S. An automated electrophysiological assay for differentiating Ca(v)2.2 inhibitors based on state dependence and kinetics. Assay and Drug Development Technologies. 10: 542-50. PMID 22428804 DOI: 10.1089/adt.2011.437 |
0.585 |
|
| 2012 |
Scott VE, Vortherms TA, Niforatos W, Swensen AM, Neelands T, Milicic I, Banfor PN, King A, Zhong C, Simler G, Zhan C, Bratcher N, Boyce-Rustay JM, Zhu CZ, Bhatia P, et al. A-1048400 is a novel, orally active, state-dependent neuronal calcium channel blocker that produces dose-dependent antinociception without altering hemodynamic function in rats. Biochemical Pharmacology. 83: 406-18. PMID 22153861 DOI: 10.1016/j.bcp.2011.10.019 |
0.351 |
|
| 2010 |
Abbadie C, McManus OB, Sun SY, Bugianesi RM, Dai G, Haedo RJ, Herrington JB, Kaczorowski GJ, Smith MM, Swensen AM, Warren VA, Williams B, Arneric SP, Eduljee C, Snutch TP, et al. Analgesic effects of a substituted N-triazole oxindole (TROX-1), a state-dependent, voltage-gated calcium channel 2 blocker. The Journal of Pharmacology and Experimental Therapeutics. 334: 545-55. PMID 20439438 DOI: 10.1124/Jpet.110.166363 |
0.356 |
|
| 2008 |
Dai G, Haedo RJ, Warren VA, Ratliff KS, Bugianesi RM, Rush A, Williams ME, Herrington J, Smith MM, McManus OB, Swensen AM. A high-throughput assay for evaluating state dependence and subtype selectivity of Cav2 calcium channel inhibitors. Assay and Drug Development Technologies. 6: 195-212. PMID 18471074 DOI: 10.1089/adt.2008.136 |
0.37 |
|
| 2007 |
Richards KS, Swensen AM, Lipscombe D, Bommert K. Novel CaV2.1 clone replicates many properties of Purkinje cell CaV2.1 current. The European Journal of Neuroscience. 26: 2950-61. PMID 18001290 DOI: 10.1111/J.1460-9568.2007.05912.X |
0.668 |
|
| 2005 |
Swensen AM, Bean BP. Robustness of burst firing in dissociated purkinje neurons with acute or long-term reductions in sodium conductance. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 3509-20. PMID 15814781 DOI: 10.1523/Jneurosci.3929-04.2005 |
0.487 |
|
| 2003 |
Swensen AM, Bean BP. Ionic mechanisms of burst firing in dissociated Purkinje neurons. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 23: 9650-63. PMID 14573545 DOI: 10.1523/Jneurosci.23-29-09650.2003 |
0.446 |
|
| 2001 |
Swensen AM, Marder E. Modulators with convergent cellular actions elicit distinct circuit outputs. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 21: 4050-8. PMID 11356892 DOI: 10.1523/Jneurosci.21-11-04050.2001 |
0.618 |
|
| 2001 |
Nusbaum MP, Blitz DM, Swensen AM, Wood D, Marder E. The roles of co-transmission in neural network modulation. Trends in Neurosciences. 24: 146-54. PMID 11182454 DOI: 10.1016/S0166-2236(00)01723-9 |
0.639 |
|
| 2000 |
Swensen AM, Marder E. Multiple peptides converge to activate the same voltage-dependent current in a central pattern-generating circuit. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 20: 6752-9. PMID 10995818 DOI: 10.1523/Jneurosci.20-18-06752.2000 |
0.606 |
|
| 2000 |
Swensen AM, Golowasch J, Christie AE, Coleman MJ, Nusbaum MP, Marder E. GABA and responses to GABA in the stomatogastric ganglion of the crab Cancer borealis. The Journal of Experimental Biology. 203: 2075-92. PMID 10862721 |
0.631 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2012 |
Shao PP, Ye F, Chakravarty PK, Varughese DJ, Herrington JB, Dai G, Bugianesi RM, Haedo RJ, Swensen AM, Warren VA, Smith MM, Garcia ML, McManus OB, Lyons KA, Li X, et al. Aminopiperidine sulfonamide Cav2.2 channel inhibitors for the treatment of chronic pain. Journal of Medicinal Chemistry. 55: 9847-55. PMID 23098566 DOI: 10.1021/jm301056k |
0.28 |
|
| 2011 |
Vortherms TA, Swensen AM, Niforatos W, Limberis JT, Neelands TR, Janis RS, Thimmapaya R, Donnelly-Roberts DL, Namovic MT, Zhang D, Brent Putman C, Martin RL, Surowy CS, Jarvis MF, Scott VE. Comparative analysis of inactivated-state block of N-type (Ca(v)2.2) calcium channels. Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]. 60: 683-93. PMID 21394563 DOI: 10.1007/s00011-011-0322-9 |
0.275 |
|
| 2013 |
Hermann D, Mezler M, Swensen AM, Bruehl C, Obergrußerger A, Wicke K, Schoemaker H, Gross G, Draguhn A, Nimmrich V. Establishment of a secondary screening assay for P/Q-type calcium channel blockers. Combinatorial Chemistry & High Throughput Screening. 16: 233-43. PMID 23228050 DOI: 10.2174/1386207311316030008 |
0.269 |
|
| 2012 |
Swensen AM, Herrington J, Bugianesi RM, Dai G, Haedo RJ, Ratliff KS, Smith MM, Warren VA, Arneric SP, Eduljee C, Parker D, Snutch TP, Hoyt SB, London C, Duffy JL, et al. Characterization of the substituted N-triazole oxindole TROX-1, a small-molecule, state-dependent inhibitor of Ca(V)2 calcium channels. Molecular Pharmacology. 81: 488-97. PMID 22188924 DOI: 10.1124/Mol.111.075226 |
0.257 |
|
| 2010 |
Schmalhofer WA, Swensen AM, Thomas BS, Felix JP, Haedo RJ, Solly K, Kiss L, Kaczorowski GJ, Garcia ML. A pharmacologically validated, high-capacity, functional thallium flux assay for the human Ether-Ã -go-go related gene potassium channel. Assay and Drug Development Technologies. 8: 714-26. PMID 21158686 DOI: 10.1089/adt.2010.0351 |
0.249 |
|
| 2012 |
Mezler M, Hermann D, Swensen AM, Draguhn A, Terstappen GC, Gross G, Schoemaker H, Freiberg G, Pratt S, Gopalakrishnan SM, Nimmrich V. Development and validation of a fluorescence-based HTS assay for the identification of P/Q-type calcium channel blockers. Combinatorial Chemistry & High Throughput Screening. 15: 372-85. PMID 22272661 DOI: 10.2174/138620712800194503 |
0.246 |
|
| 2012 |
Beebe X, Darczak D, Henry RF, Vortherms T, Janis R, Namovic M, Donnelly-Roberts D, Kage KL, Surowy C, Milicic I, Niforatos W, Swensen A, Marsh KC, Wetter JM, Franklin P, et al. Synthesis and SAR of 4-aminocyclopentapyrrolidines as N-type Ca²⺠channel blockers with analgesic activity. Bioorganic & Medicinal Chemistry. 20: 4128-39. PMID 22626552 DOI: 10.1016/j.bmc.2012.04.057 |
0.245 |
|
| 2011 |
Tyagarajan S, Chakravarty PK, Park M, Zhou B, Herrington JB, Ratliff K, Bugianesi RM, Williams B, Haedo RJ, Swensen AM, Warren VA, Smith M, Garcia M, Kaczorowski GJ, McManus OB, et al. A potent and selective indole N-type calcium channel (Ca(v)2.2) blocker for the treatment of pain. Bioorganic & Medicinal Chemistry Letters. 21: 869-73. PMID 21195616 DOI: 10.1016/j.bmcl.2010.11.067 |
0.245 |
|
| 2013 |
Beebe X, Yeung CM, Darczak D, Shekhar S, Vortherms TA, Miller L, Milicic I, Swensen AM, Zhu CZ, Banfor P, Wetter JM, Marsh KC, Jarvis MF, Scott VE, Schrimpf MR, et al. Synthesis and SAR of 4-aminocyclopentapyrrolidines as orally active N-type calcium channel inhibitors for inflammatory and neuropathic pain. Bioorganic & Medicinal Chemistry Letters. 23: 4857-61. PMID 23876987 DOI: 10.1016/J.Bmcl.2013.06.074 |
0.21 |
|
| 2018 |
Gees M, Musch S, Van der Plas S, Wesse AS, Vandevelde A, Verdonck K, Mammoliti O, Hwang TC, Sonck K, Stouten P, Swensen AM, Jans M, Van der Schueren J, Nelles L, Andrews M, et al. Identification and Characterization of Novel CFTR Potentiators. Frontiers in Pharmacology. 9: 1221. PMID 30416447 DOI: 10.3389/fphar.2018.01221 |
0.201 |
|
| 2007 |
Priest BT, Swensen AM, McManus OB. Automated electrophysiology in drug discovery. Current Pharmaceutical Design. 13: 2325-37. PMID 17692004 DOI: 10.2174/138161207781368701 |
0.193 |
|
| 2014 |
Garcia ML, Priest BT, Alonso-Galicia M, Zhou X, Felix JP, Brochu RM, Bailey T, Thomas-Fowlkes B, Liu J, Swensen A, Pai LY, Xiao J, Hernandez M, Hoagland K, Owens K, et al. Pharmacologic inhibition of the renal outer medullary potassium channel causes diuresis and natriuresis in the absence of kaliuresis. The Journal of Pharmacology and Experimental Therapeutics. 348: 153-64. PMID 24142912 DOI: 10.1124/jpet.113.208603 |
0.191 |
|
| 2016 |
Tang H, Zhu Y, Teumelsan N, Walsh SP, Shahripour A, Priest BT, Swensen AM, Felix JP, Brochu RM, Bailey T, Thomas-Fowlkes B, Pai LY, Hampton C, Corona A, Hernandez M, et al. Discovery of MK-7145, an Oral Small Molecule ROMK Inhibitor for the Treatment of Hypertension and Heart Failure. Acs Medicinal Chemistry Letters. 7: 697-701. PMID 27437080 DOI: 10.1021/acsmedchemlett.6b00122 |
0.178 |
|
| 2015 |
Walsh SP, Shahripour A, Tang H, Teumelsan N, Frie J, Zhu Y, Priest BT, Swensen AM, Liu J, Margulis M, Visconti R, Weinglass A, Felix JP, Brochu RM, Bailey T, et al. Discovery of a Potent and Selective ROMK Inhibitor with Pharmacokinetic Properties Suitable for Preclinical Evaluation. Acs Medicinal Chemistry Letters. 6: 747-52. PMID 26191360 DOI: 10.1021/ml500440u |
0.156 |
|
| 2017 |
Wang X, Liu B, Searle X, Yeung C, Bogdan AR, Greszler SN, Singh A, Fan Y, Swensen AM, Vortherms T, Balut C, Jia Y, Desino KE, Gao W, Yong H, et al. Discovery of 4-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis. Journal of Medicinal Chemistry. PMID 29251932 DOI: 10.1021/Acs.Jmedchem.7B01339 |
0.148 |
|
| 2013 |
Tang H, de Jesus RK, Walsh SP, Zhu Y, Yan Y, Priest BT, Swensen AM, Alonso-Galicia M, Felix JP, Brochu RM, Bailey T, Thomas-Fowlkes B, Zhou X, Pai LY, Hampton C, et al. Discovery of a novel sub-class of ROMK channel inhibitors typified by 5-(2-(4-(2-(4-(1H-Tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one. Bioorganic & Medicinal Chemistry Letters. 23: 5829-32. PMID 24075732 DOI: 10.1016/j.bmcl.2013.08.104 |
0.138 |
|
| 2013 |
Shao PP, Ye F, Chakravarty PK, Herrington JB, Dai G, Bugianesi RM, Haedo RJ, Swensen AM, Warren VA, Smith MM, Garcia ML, McManus OB, Lyons KA, Li X, Green M, et al. Improved Cav2.2 Channel Inhibitors through a gem-Dimethylsulfone Bioisostere Replacement of a Labile Sulfonamide. Acs Medicinal Chemistry Letters. 4: 1064-8. PMID 24900606 DOI: 10.1021/ml4002612 |
0.134 |
|
| 2016 |
Walsh SP, Shahripour A, Tang H, de Jesus RK, Teumelsan N, Zhu Y, Frie J, Priest BT, Swensen AM, Alonso-Galicia M, Felix JP, Brochu RM, Bailey T, Thomas-Fowlkes B, Zhou X, et al. Differentiation of ROMK potency from hERG potency in the phenacetyl piperazine series through heterocycle incorporation. Bioorganic & Medicinal Chemistry Letters. PMID 27017115 DOI: 10.1016/j.bmcl.2016.03.035 |
0.12 |
|
| 2019 |
Singh AK, Fan Y, Balut C, Alani S, Manelli A, Swensen AM, Jia Y, Neelands TR, Vortherms TA, Liu B, Searle XB, Wang X, Gao W, Hwang TC, Ren H, et al. Biological characterization of F508delCFTR protein processing by the CFTR Corrector ABBV-2222/GLPG2222. The Journal of Pharmacology and Experimental Therapeutics. PMID 31732698 DOI: 10.1124/Jpet.119.261800 |
0.118 |
|
| 2008 |
Weinglass AB, Swensen AM, Liu J, Schmalhofer W, Thomas A, Williams B, Ross L, Hashizume K, Kohler M, Kaczorowski GJ, Garcia ML. A high-capacity membrane potential FRET-based assay for the sodium-coupled glucose co-transporter SGLT1. Assay and Drug Development Technologies. 6: 255-62. PMID 18471079 DOI: 10.1089/Adt.2008.125 |
0.111 |
|
| 2016 |
Zhu Y, de Jesus RK, Tang H, Walsh SP, Jiang J, Gu X, Teumelsan N, Shahripour A, Pio B, Ding FX, Ha S, Priest BT, Swensen AM, Alonso-Galicia M, Felix JP, et al. Discovery of a potent and selective ROMK inhibitor with improved pharmacokinetic properties based on an octahydropyrazino[2,1-c][1,4]oxazine scaffold. Bioorganic & Medicinal Chemistry Letters. PMID 27839686 DOI: 10.1016/j.bmcl.2016.10.064 |
0.105 |
|
| 2015 |
Walsh SP, Shahripour A, Tang H, Teumelsan N, Frie J, Zhu Y, Priest BT, Swensen AM, Liu J, Margulis M, Visconti R, Weinglass A, Felix JP, Brochu RM, Bailey T, et al. Discovery of a potent and selective ROMK inhibitor with pharmacokinetic properties suitable for preclinical evaluation Acs Medicinal Chemistry Letters. 6: 747-752. DOI: 10.1021/ml500440u |
0.1 |
|
| 2019 |
Scanio MJC, Searle XB, Liu B, Koenig JR, Altenbach R, Gfesser GA, Bogdan A, Greszler S, Zhao G, Singh A, Fan Y, Swensen AM, Vortherms T, Manelli A, Balut C, et al. Discovery of ABBV/GLPG-3221, a Potent Corrector of CFTR for the Treatment of Cystic Fibrosis. Acs Medicinal Chemistry Letters. 10: 1543-1548. PMID 31749908 DOI: 10.1021/Acsmedchemlett.9B00377 |
0.098 |
|
| 2019 |
Wong YL, LeBon L, Basso AM, Kohlhaas KL, Nikkel AL, Robb HM, Donnelly-Roberts DL, Prakash J, Swensen AM, Rubinstein ND, Krishnan S, McAllister FE, Haste NV, O'Brien JJ, Roy M, et al. eIF2B activator prevents neurological defects caused by a chronic integrated stress response. Elife. 8. PMID 30624206 DOI: 10.7554/Elife.42940 |
0.083 |
|
| 2024 |
Asundi J, Zhang C, Donnelly-Roberts D, Solorio JZ, Challagundla M, Connelly C, Boch C, Chen J, Richter M, Maneshi MM, Swensen AM, Lebon L, Schiffmann R, Sanyal S, Sidrauski C, et al. GDF15 is a dynamic biomarker of the integrated stress response in the central nervous system. Cns Neuroscience & Therapeutics. 30: e14600. PMID 38357857 DOI: 10.1111/cns.14600 |
0.071 |
|
| 2022 |
Scanio MJC, Searle XB, Liu B, Koenig JR, Altenbach RJ, Gfesser GA, Bogdan A, Greszler S, Zhao G, Singh A, Fan Y, Swensen AM, Vortherms T, Manelli A, Balut C, et al. Discovery and SAR of 4-aminopyrrolidine-2-carboxylic acid correctors of CFTR for the treatment of cystic fibrosis. Bioorganic & Medicinal Chemistry Letters. 72: 128843. PMID 35688367 DOI: 10.1016/j.bmcl.2022.128843 |
0.065 |
|
| Hide low-probability matches. |